Melad Farraha

Dr. Melad Farraha

Westmead Institute for Medical Research, Sydney, New South Wales, Australia
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TLThi Yen Loan Le
Thi Yen Loan Le
HPHilda A. Pickett
Hilda A. Pickett
AYAndrian Yang
Andrian Yang
JHJoshua W. K. Ho
Joshua W. K. Ho
STSujitha Thavapalachandran
Sujitha Thavapalachandran
JCJames J. H. Chong
James J. H. Chong
We have previously reported a subpopulation of mesenchymal stromal cells (MSCs) within the platelet-derived growth factor receptor-alpha (PDGFRα)/CD90 co-expressing cardiac interstitial and adventitial cell fraction. Here we further characterise PDGFRα/CD90-expressing cardiac MSCs (PDGFRα + cMSCs) and use human telomerase reverse transcriptase (hTERT) over-expression to increase cMSCs ability to repair the heart after induced myocardial infarction. hTERT over-expression in PDGFRα + cardiac MSCs (hTERT + PDGFRα + cMSCs) modulates cell differentiation, proliferation, survival and angiogenesis related genes. In vivo, transplantation of hTERT + PDGFRα + cMSCs in athymic rats significantly increased left ventricular function, reduced scar size, increased angiogenesis and proliferation of both cardiomyocyte and non-myocyte cell fractions four weeks after myocardial infarction. In contrast, transplantation of mutant hTERT + PDGFRα + cMSCs (which generate catalytically-inactive telomerase) failed to replicate this cardiac functional improvement, indicating a telomerase-dependent mechanism. There was no hTERT + PDGFRα + cMSCs engraftment 14 days after transplantation indicating functional improvement occurred by paracrine mechanisms. Mass spectrometry on hTERT + PDGFRα + cMSCs conditioned media showed increased proteins associated with matrix modulation, angiogenesis, cell proliferation/survival/adhesion and innate immunity function. Our study shows that hTERT can activate pro-regenerative signalling within PDGFRα + cMSCs and enhance cardiac repair after myocardial infarction. An increased understanding of hTERT’s role in mesenchymal stromal cells from various organs will favourably impact clinical regenerative and anti-cancer therapies.

1 October 2017 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
RSRahul Samanta
Rahul Samanta
SKSaurabh Kumar
Saurabh Kumar
WCWilliam Chik
William Chik
PQPierre Qian
Pierre Qian
MBMichael A. Barry
Michael A. Barry
JPJim Pouliopoulos
Jim Pouliopoulos
Background: Recent studies have demonstrated that intramyocardial adipose tissue (IMAT) may contribute to ventricular electrophysiological remodeling in patients with chronic myocardial infarction. Using an ovine model of myocardial infarction, we aimed to determine the influence of IMAT on scar tissue identification during endocardial contact mapping and optimal voltage-based mapping criteria for defining IMAT dense regions. Method and Results: In 7 sheep, left ventricular endocardial and transmural mapping was performed 84 weeks (15–111 weeks) post-myocardial infarction. Spearman rank correlation coefficient was used to assess the relationship between endocardial contact electrogram amplitude and histological composition of myocardium. Receiver operator characteristic curves were used to derive optimal electrogram thresholds for IMAT delineation during endocardial mapping and to describe the use of endocardial mapping for delineation of IMAT dense regions within scar. Endocardial electrogram amplitude correlated significantly with IMAT (unipolar r =−0.48±0.12, P <0.001; bipolar r =−0.45±0.22, P =0.04) but not collagen (unipolar r =−0.36±0.24, P =0.13; bipolar r =−0.43±0.31, P =0.16). IMAT dense regions of myocardium reliably identified using endocardial mapping with thresholds of <3.7 and <0.6 mV, respectively, for unipolar, bipolar, and combined modalities (single modality area under the curve=0.80, P <0.001; combined modality area under the curve=0.84, P <0.001). Unipolar mapping using optimal thresholding remained significantly reliable (area under the curve=0.76, P <0.001) during mapping of IMAT, confined to putative scar border zones (bipolar amplitude, 0.5–1.5 mV). Conclusions: These novel findings enhance our understanding of the confounding influence of IMAT on endocardial scar mapping. Combined bipolar and unipolar voltage mapping using optimal thresholds may be useful for delineating IMAT dense regions of myocardium, in postinfarct cardiomyopathy.

1 October 2020 in Clinical Therapeutics
Verified
Journal Article
Closed access
DRDhanya Ravindran
Dhanya Ravindran
CKCindy Kok
Cindy Kok
Melad FarrahaMelad Farraha
Melad Farraha
DSDinesh Selvakumar
Dinesh Selvakumar
ZCZoe E. Clayton
Zoe E. Clayton
EKEddy Kizana
Eddy Kizana

1 August 2016 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
Melad FarrahaMelad Farraha
Melad Farraha
JCJames J.H. Chong
James J.H. Chong
EKEddy Kizana
Eddy Kizana

Verified
Journal Article
Open access
PDF file
Melad FarrahaMelad Farraha
Melad Farraha
SKSaurabh Kumar
Saurabh Kumar
JCJames Chong
James Chong
HCHee Cheol Cho
Hee Cheol Cho
EKEddy Kizana
Eddy Kizana
Bradycardia arising from pacemaker dysfunction can be debilitating and life threatening. Electronic pacemakers serve as effective treatment options for pacemaker dysfunction. They however present their own limitations and complications. This has motivated research into discovering more effective and innovative ways to treat pacemaker dysfunction. Gene therapy is being explored for its potential to treat various cardiac conditions including cardiac arrhythmias. Gene transfer vectors with increasing transduction efficiency and biosafety have been developed and trialed for cardiovascular disease treatment. With an improved understanding of the molecular mechanisms driving pacemaker development, several gene therapy targets have been identified to generate the phenotypic changes required to correct pacemaker dysfunction. This review will discuss the gene therapy vectors in use today along with methods for their delivery. Furthermore, it will evaluate several gene therapy strategies attempting to restore biological pacing, having the potential to emerge as viable therapies for pacemaker dysfunction.

29 August 2019 in Gene Therapy
Verified
Journal Article
Closed access
PDF file
Melad FarrahaMelad Farraha
Melad Farraha
MBMichael A. Barry
Michael A. Barry
JLJuntang Lu
Juntang Lu
JPJim Pouliopoulos
Jim Pouliopoulos
TLThi Y. L. Le
Thi Y. L. Le
EKEddy Kizana
Eddy Kizana